Literature DB >> 19219538

The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion.

Hanna E Silber1, Maria C Kjellsson, Mats O Karlsson.   

Abstract

It has been shown that when using the FOCE method in NONMEM, the likelihood ratio test (LRT) can be sensitive to the use of an inappropriate estimation method in that ignoring an existing eta-epsilon interaction leads to actual significance levels for type I errors being higher than the nominal levels. The objective of this study was to assess through simulations the LRT sensitivity to various types of residual error model misspecifications in both continuous and categorical data. The study contained two parts, simulations based on continuous and categorical data. Data sets containing 250 individuals with up to 24 observations per individual were simulated multiple times (1000) with different types of residual error models for the continuous data and different strength of correlation between observations for the categorical data. The data sets were analyzed using either the correct or a simpler (incorrect) model with or without addition of a covariate. The type I error rate of inclusion of the non-informative covariate on the 5% level was calculated as the number of runs where the drop in the objective function value (OFV) was larger than 3.84 when the covariate relationship was included in the model using the correct or the incorrect model. The difference in OFV between the model with the correct and the incorrect structure was also calculated as a measure of the residual error model misspecification. For continuous data the FOCE method was used in most cases (with interaction when appropriate). The Laplacian estimation method was used for one of the continuous models and for categorical data. The results showed that the residual error model misspecifications when the erroneous model was used were pronounced, as indicated by the OFV being substantially higher than for the corresponding correct models. The significance levels of the LRT with the incorrect model were appropriate in all cases but ignoring (serial) correlations between observations (continuous and categorical data) as well as when the eta-epsilon interaction was ignored (which has previously been shown, continuous data). When ignoring correlation, the type I error rates were shown to be sensitive to the correlation strength, the number of observations per individual and the magnitude of the inter-individual variability on clearance. We conclude that the LRT appears robust towards all tested cases, but ignoring (serial) correlations between observations and eta-epsilon interaction.

Entities:  

Mesh:

Year:  2009        PMID: 19219538     DOI: 10.1007/s10928-009-9112-1

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  15 in total

1.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Comput Methods Programs Biomed       Date:  1999-01       Impact factor: 5.428

2.  The need for mixed-effects modeling with population dichotomous data.

Authors:  I Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-08       Impact factor: 2.745

3.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

4.  Assessment of type I error rates for the statistical sub-model in NONMEM.

Authors:  Ulrika Wählby; M René Bouw; E Niclas Jonsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

5.  Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED.

Authors:  Siv Jönsson; Maria C Kjellsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-08       Impact factor: 2.745

Review 6.  Mixed effects versus fixed effects modelling of binary data with inter-subject variability.

Authors:  Valda Murphy; Adrian Dunne
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.745

7.  Use of prior information to stabilize a population data analysis.

Authors:  Per O Gisleskog; Mats O Karlsson; Stuart L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-12       Impact factor: 2.745

8.  The importance of modeling interoccasion variability in population pharmacokinetic analyses.

Authors:  M O Karlsson; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

9.  A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep.

Authors:  M O Karlsson; R C Schoemaker; B Kemp; A F Cohen; J M van Gerven; B Tuk; C C Peck; M Danhof
Journal:  Clin Pharmacol Ther       Date:  2000-08       Impact factor: 6.875

10.  Modelling a spontaneously reported side effect by use of a Markov mixed-effects model.

Authors:  Per-Henrik Zingmark; Matts Kågedal; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.410

View more
  12 in total

1.  Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis.

Authors:  Hanna E Silber; Claudia Burgener; Ingrid M Letellier; Mathieu Peyrou; Martin Jung; Jonathan N King; Philippe Gruet; Jerome M Giraudel
Journal:  Pharm Res       Date:  2010-10-05       Impact factor: 4.200

2.  Serial correlation in optimal design for nonlinear mixed effects models.

Authors:  Joakim Nyberg; Richard Höglund; Martin Bergstrand; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-03-14       Impact factor: 2.745

3.  Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation.

Authors:  Jae Eun Ahn; Jonathan L French
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-04-01       Impact factor: 2.745

4.  A new exact test for the evaluation of population pharmacokinetic and/or pharmacodynamic models using random projections.

Authors:  Celine Marielle Laffont; Didier Concordet
Journal:  Pharm Res       Date:  2011-04-14       Impact factor: 4.200

5.  Model-Based Residual Post-Processing for Residual Model Identification.

Authors:  Moustafa M A Ibrahim; Rikard Nordgren; Maria C Kjellsson; Mats O Karlsson
Journal:  AAPS J       Date:  2018-07-02       Impact factor: 4.009

6.  A Bayesian hierarchical nonlinear mixture model in the presence of artifactual outliers in a population pharmacokinetic study.

Authors:  Leena Choi; Brian S Caffo; Utkarsh Kohli; Pratik Pandharipande; Daniel Kurnik; E Wesley Ely; C Michael Stein
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-08-17       Impact factor: 2.745

7.  Predictive performance for population models using stochastic differential equations applied on data from an oral glucose tolerance test.

Authors:  Jonas B Møller; Rune V Overgaard; Henrik Madsen; Torben Hansen; Oluf Pedersen; Steen H Ingwersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-12-16       Impact factor: 2.745

8.  Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.

Authors:  Qi Wang; Kamalika Banerjee; Grygoriy Vasilinin; J F Marier; Jacqueline A Gibbons
Journal:  J Clin Pharmacol       Date:  2018-12-19       Impact factor: 3.126

9.  Use of a linearization approximation facilitating stochastic model building.

Authors:  Elin M Svensson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-03-13       Impact factor: 2.745

10.  A strategy for residual error modeling incorporating scedasticity of variance and distribution shape.

Authors:  Anne-Gaëlle Dosne; Martin Bergstrand; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-12-17       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.